



VANDERBILT
UNIVERSITY®

Evolving moldy murderers: How species in *Aspergillus* section *Fumigati* became pathogenic and identifying the genetic elements responsible

Matthew E. Mead*, Jacob L. Steenwyk*, Lilian P. Silva†, Laure N.A. Ries†, Sonja L. Knowles#, Huzefa A. Raja#, Nicholas H. Oberlies#, Gustavo H. Goldman†, and Antonis Rokas#

*Department of Biological Sciences, Vanderbilt University, Nashville, TN, USA; #Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, NC, USA; †Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Brazil




@fungalmatt

Abstract


- Approximately 70% of all *Aspergillus* infections are caused by *A. fumigatus* whereas the remaining 30% stem from other species in the genus.
- Some pathogens are related to *A. fumigatus* and also belong in taxonomic section *Fumigati*; however, the majority of species in section *Fumigati* are not pathogenic.
- To study the evolution of pathogenicity in section *Fumigati* and identify targets for future therapeutics, we utilized comparative genomics, in vitro phenotyping, natural product chemistry, and an insect model of aspergillosis.
- Phylogenies of section *Fumigati* suggest that pathogenicity has independently evolved many times.
- A. fischeri*, a non-pathogenic species very closely related to *A. fumigatus*, differs with regard to *A. fumigatus* for multiple disease-relevant traits.
- However, most of the *A. fumigatus* genes known to be associated with virulence are highly conserved in non-pathogens, and functional testing of multiple conserved virulence factors showed that they do not affect the pathogenic potential of *A. fischeri*.
- Many genes in pathogenic species exhibit higher rates of evolution than their homologs in lowly (or non-) pathogenic species.
- Our results establish a broad, comparative framework for explaining why *A. fumigatus* is such a potent killer and more generally, how major fungal pathogens evolve from historically innocuous organisms.

Most *A. fumigatus* genes known to be associated with virulence are highly conserved across species in section *Fumigati*, including in non-pathogens




Heatmap of gene count in virulence-related gene families. Highly similar genes were placed in orthologous groups and were considered proxies for gene families. Virulence-related genes from *A. fumigatus* were acquired from the literature as well as the PHI-base database (4). Only those gene families that exhibited some change in gene family number across the species of interest (116/201) are shown. Note, there are no "*A. fumigatus*-Specific", "Section *Fumigati*-Specific", or "Pathogen-Specific" gene families. Left, cladogram of species based on their phylogenetic relationships.

Pathogenicity in section *Fumigati* has evolved multiple times independently




A. Reconstruction of the ability to cause human disease on a 4-gene phylogeny of section *Fumigati*. From (1) and (2). **B.** A 3,601-gene phylogeny of 5 outgroup species and all genomes available (as of April 27, 2019) from section *Fumigati* has multiple non-pathogenic strains interspersed with pathogens, suggesting that pathogenesis has evolved multiple times.

A. fischeri contains the gliotoxin biosynthetic gene cluster and produces gliotoxin in the same conditions as *A. fumigatus*





A. *A. fischeri* contains a biosynthetic gene cluster homologous to the one known to produce the toxin gliotoxin in *A. fumigatus*. **B.** Extracted chromatograms (using the protonated mass of gliotoxin) demonstrating the biosynthesis of gliotoxin in *A. fischeri* and *A. fumigatus*. The first panel shows the analysis of the gliotoxin standard for comparison. NL - normalization level (i.e. base peak intensity). From (5).

Deletion of a conserved virulence-related gene from *A. fumigatus* does not affect pathogenicity in *A. fischeri*



A. *A. laeA* is required for full virulence during *A. fumigatus* infection of immunocompromised mice. Redrawn from (6). **B.** Deletion of *laeA* in *A. fischeri* does not alter its virulence. Cumulative survival curves of moth (*Galleria mellonella*) larvae inoculated with asexual spores from either a $\Delta laeA$ mutant or wild-type (WT) *A. fischeri* NRRL 181 strain. Comparisons of moth cumulative survival when infected with either strain revealed no statistically significant differences (P -value = 0.30; log-rank test). For the inoculations, 10 moths were infected per group. From (5).

A. fischeri, a very close but non-pathogenic relative of *A. fumigatus*, exhibits divergent infection-relevant phenotypes




C.

Secondary Metabolite	Produced by <i>A. fumigatus</i>	Produced by <i>A. fischeri</i>
Fumagillin	+	-
Pseurotin	+	-
Acetylazonalenin	+	+
Fumitremogin A	+	+
Fumitremogin B	+	+
Verruculogen	+	+
C-11 epimer of verruculogen TR2	-	+
13-O-Fumitremogin B	-	+
Sartorypyrone A	-	+
Sartorypyrone E	-	+
14-Epi-sartorypyrone A	-	+
Azonalenin	-	+

A. *A. fischeri* is less able to thrive at infection-relevant temperatures. Error bars indicate standard deviations between biological duplicates (** P -value < 0.005 in a paired, equal variance student t -test). **B.** *A. fumigatus* is more tolerant of a molecule used for immune defense (hydrogen peroxide) than *A. fischeri*. **C.** While *A. fischeri* can produce some of the same secondary metabolites as *A. fumigatus*, it also produces novel compounds. All data from (3).

Genes in more-pathogenic species exhibit faster rates of evolution than the same genes in less-pathogenic species.



A. Distribution of dN/dS values for 1,743 single-copy gene families in section *Fumigati* species. Only the 1,743 genes that rejected ($p < 0.01$) the null hypothesis of a single dN/dS rate across the phylogeny are shown. *, adjusted P -value < 0.0001 for a Wilcoxon Signed-Rank Test.

References

- Hubka, V., Barrs, V., Dudová, Z., Sklenář, F., Kubátová, A., Matsuzawa, T., et al. (2018). Unravelling species boundaries in the *Aspergillus viridinutans* complex (section *Fumigati*): opportunistic human and animal pathogens capable of interspecific hybridization. *Persoonia - Molecular Phylogeny and Evolution of Fungi*. <http://doi.org/10.3767/persoonia.2018.41.08>
- Rokas, A., Mead, M.E., Steenwyk, J.L., Oberlies, N.H., Goldman, G.H. (2020). Evolving Moldy murderers: *Aspergillus* section *Fumigati* as a model for studying the repeated evolution of fungal pathogenicity. *PLoS Pathogens*; in press.
- Mead, M.E., Knowles, S.L., Raja, H.A., Beattie, S.R., Kowalski, C.H., Steenwyk, J.L., et al. (2019). Characterizing the Pathogenic, Genomic, and Chemical Traits of *Aspergillus fischeri*, a Close Relative of the Major Human Fungal Pathogen *Aspergillus fumigatus*. *mSphere*, 4(1). <http://doi.org/10.1128/mSphere.00018-19>
- Urban, M., Cuzick, A., Rutherford, K., Irvine, A., Pedro, H., Pant, R., et al. (2017). PHI-base: a new interface and further additions for the multi-species pathogen-host interactions database. *Nucleic Acids Research*, 45(D1), D604–D610. <http://doi.org/10.1093/nar/gkw1089>
- Knowles, S.J., Mead, M.E., Pereira Silva, L., Raja, H.A., Steenwyk, J.L., Goldman, G.H., et al. (2020). Gliotoxin, a known virulence factor in the major human pathogen *Aspergillus fumigatus*, is also biosynthesized by the non-pathogenic relative *A. fischeri*. *mBio*; in press
- Bok, J.W., Balajee, S.A., Marr, K.A., Andes, D., Nielsen, K.F., Frisvad, J.C., & Keller, N.P. (2005). *laeA*, a regulator of morphogenetic fungal virulence factors. *Eukaryotic Cell*, 4(9), 1574–1582. <http://doi.org/10.1128/EC.4.9.1574-1582.2005>

Funding Sources

MEM, JLS, and AR were supported by a Vanderbilt University Discovery Grant. J.L.S. and A.R. were supported by the Howard Hughes Medical Institute through the James H. Gilliam Fellowships for Advanced Study program. Research in AR's lab is also supported by the National Science Foundation (DEB-1442113), the Guggenheim Foundation, and the Burroughs Wellcome Fund. S.L.K. was supported by the National Center for Complementary and Integrative Health, a component of the National Institutes of Health, under award number F31AT010558. GHG was supported by grants from Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), both from Brazil.